Previous studies have confirmed the therapeutic effects of bone marrow stromal cells (BMSCs) transplantation on cerebral ischemia. However, the proliferative, differentiative, and homing capacity of BMSC from the elderly are significantly reduced, especially after several passages expansion in vitro. In this study, by introducing lentivirus-mediated hTERT and VEGF genes to modify human BMSCs from aged donors, we observed extended lifespan, promoted angiogenic capacity while less enhanced tumorigenicity of the genetically engineering BMSCs. These results therefore suggest that the modification of aged BMSCs by dual expression of hTERT and VEGF may be used for autologous cell replacement for ischemic cerebrovascular disease in elderly patients.
Keywords: BCA; Bone marrow stromal cell; ELISA; FACS; Genetic engineering; IS; LP; MOI; MSC; PDL; TERC; TRAP; VEGF; bicinchoninic acid; enzyme-linked immunosorbent assay; fluorescence-activated cell sorting; hBMSC; hTERT; hTRET; human bone marrow stromal cell; human telomerase reverse transcriptase; internal standard; lentiviral particle; marrow stromal cell; multiplicity of infection; population doubling level; telomerase RNA component; telomeric repeat amplification protocol; vascular endothelial growth factor.
Copyright © 2013 Elsevier Inc. All rights reserved.